Vaxcyte Stock
Vaxcyte, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Grant E. Pickering
- Employees
- 507
- Market cap
- $9.8 B
- IPO
- 12/06/2020
- Web
- vaxcyte.com
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage headquartered in San Carlos, California. Founded in 2013, the organization was initially established as SutroVax, Inc. and officially rebranded as Vaxcyte, Inc. in May 2020. The company is dedicated to creating innovative protein-based vaccines…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Vaxcyte stock: price history
1D
-2.5%
1W
-10.9%
1M
+8.3%
6M
+2.0%
YTD
+37.9%
1Y
+46.0%
2Y
-46.1%
5Y
+160.6%
10Y
–
Next earnings date
Next earnings date
03/11/2026 (in 17 days)
Volatility around earnings
~0% stronger price swings than usual
Vaxcyte stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Ask the agents about Vaxcyte
Analyst assessment of Vaxcyte
PRICE TARGET LOW
US$120.00
CONSENSUS
US$122.33
MEDIAN
US$122.00
PRICE TARGET HIGH
US$125.00
0
STRONG BUY
11
BUY
0
HOLD
0
SELL
0
STRONG SELL
11
TOTAL · Buy
As of: 12/10/2026
Vaxcyte stock metrics
P/E
-8.33
P/B
3.33
EV/EBITDA
-9.24
RETURN ON EQUITY
-10.3%
NET MARGIN
0.0%
DEBT/EQUITY
0.04
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
89.4%
FLOAT SHARES
137,110,671
AVG. DAILY VOLUME (30D)
2,902,992
Insider transactions (SEC)
Cowan Elvia
Wassil Jim
Wassil Jim
Cowan Elvia
Wassil Jim
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -2.5%
Forums (Reddit)
Institutional holders
Smart Money
Register for free
Register now to see which funds are invested
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Comparable stocks
Frequently asked questions about Vaxcyte stock
What does Vaxcyte do?
Vaxcyte, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Grant E. Pickering, the company employs around 507 people.
The IPO was on 12/06/2020; the stock trades on NASDAQ under the ticker PCVX.
What do analysts say about Vaxcyte stock?
11 analysts rate the stock, the consensus is Buy (as of 12/10/2026).
The average price target is US$122.33, ranging from US$120.00 to US$125.00, with a median of US$122.00.
This is an external assessment, not a statement by Market Jury.
When does Vaxcyte report next?
The next earnings date is 03/11/2026.
Around past earnings, price swings were roughly 0% stronger than usual.
Does Vaxcyte pay a dividend?
No, Vaxcyte currently does not pay a dividend.
Which stocks are comparable to Vaxcyte?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Vaxcyte stock analyzed?
Clicking "Analyze stock" lets five strategies assess Vaxcyte against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.